Ernexa Therapeutics (ERNAW) Accumulated Expenses (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Accumulated Expenses data on file, last reported at $497000.0 in Q1 2026.

• Quarterly Accumulated Expenses rose 4041.67% year-over-year to $497000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $497000.0 (up 4041.67% YoY) and the FY2025 annual result came in at $898000.0, up 7383.33% from the prior year.
• Accumulated Expenses fell to $497000.0 in Q1 2026, from $898000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.0 million in Q3 2023 to a low of $12000.0 in Q4 2024.
• A 5-year average of $1.4 million and a median of $938000.0 in 2025 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 7383.33% in 2025, down 99.36% in 2025.
• Tracing ERNAW's Accumulated Expenses over 5 years: stood at $1.1 million in 2022, then tumbled by 83.47% to $176000.0 in 2023, then sank by 93.18% to $12000.0 in 2024, then soared by 7383.33% to $898000.0 in 2025, then plunged by 44.65% to $497000.0 in 2026.
• The last three Accumulated Expenses figures came in at $497000.0 (Q1 2026), $898000.0 (Q4 2025), and $859000.0 (Q3 2025), per Business Quant data.